160 related articles for article (PubMed ID: 17533375)
1. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.
Li XL; Arai Y; Harada H; Shima Y; Yoshida H; Rokudai S; Aikawa Y; Kimura A; Kitabayashi I
Oncogene; 2007 Nov; 26(51):7231-9. PubMed ID: 17533375
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
3. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
4. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
6. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
[TBL] [Abstract][Full Text] [Related]
7. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation.
Aikawa Y; Nguyen LA; Isono K; Takakura N; Tagata Y; Schmitz ML; Koseki H; Kitabayashi I
EMBO J; 2006 Sep; 25(17):3955-65. PubMed ID: 16917507
[TBL] [Abstract][Full Text] [Related]
8. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation.
Rui Y; Xu Z; Lin S; Li Q; Rui H; Luo W; Zhou HM; Cheung PY; Wu Z; Ye Z; Li P; Han J; Lin SC
EMBO J; 2004 Nov; 23(23):4583-94. PubMed ID: 15526030
[TBL] [Abstract][Full Text] [Related]
9. Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression.
Möller A; Sirma H; Hofmann TG; Staege H; Gresko E; Lüdi KS; Klimczak E; Dröge W; Will H; Schmitz ML
Oncogene; 2003 Nov; 22(54):8731-7. PubMed ID: 14647468
[TBL] [Abstract][Full Text] [Related]
10. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
11. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
Harada H
Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
[No Abstract] [Full Text] [Related]
12. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of homeodomain-interacting protein kinase 2 on the aorta-gonad-mesonephros hematopoiesis.
Ohtsu N; Nobuhisa I; Mochita M; Taga T
Exp Cell Res; 2007 Jan; 313(1):88-97. PubMed ID: 17064687
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
15. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.
Zhang Y; Zhang M; Yang L; Xiao Z
Leuk Res; 2007 Jan; 31(1):109-11. PubMed ID: 16678898
[TBL] [Abstract][Full Text] [Related]
16. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
Harada H; Harada Y; Tanaka H; Kimura A; Inaba T
Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679
[TBL] [Abstract][Full Text] [Related]
17. HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA.
Nardinocchi L; Puca R; Sacchi A; D'Orazi G
Biochem Biophys Res Commun; 2007 Sep; 361(1):249-55. PubMed ID: 17658469
[TBL] [Abstract][Full Text] [Related]
18. High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast.
Pavlova S; Mayer J; Koukalova H; Smardova J
Int J Oncol; 2003 Jul; 23(1):121-31. PubMed ID: 12792784
[TBL] [Abstract][Full Text] [Related]
19. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
20. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]